| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44023037 | HTLV-1 | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS44046124 | HTLV-1 | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NTRK2 |
|---|---|
| DrugBank ID | DB11823 |
| Drug Name | Esketamine |
| Target ID | BE0003605 |
| UniProt ID | Q16620 |
| Regulation Type | |
| PubMed IDs | 29736744; 22407616; 28755104 |
| Citations | Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sanchez E, Gutierrez-Rojas L, Meana JJ: Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018 May;32(5):411-420. doi: 10.1007/s40263-018-0519-3.@@Autry AE, Monteggia LM: Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012 Apr;64(2):238-58. doi: 10.1124/pr.111.005108. Epub 2012 Mar 8.@@van de Loo AJAE, Bervoets AC, Mooren L, Bouwmeester NH, Garssen J, Zuiker R, van Amerongen G, van Gerven J, Singh J, der Ark PV, Fedgchin M, Morrison R, Wajs E, Verster JC: The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study. Psychopharmacology (Berl). 2017 Nov;234(21):3175-3183. doi: 10.1007/s00213-017-4706-6. Epub 2017 Jul 28. |
| Groups | Approved; Investigational |
| Direct Classification | Chlorobenzenes |
| SMILES | CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL395091 |
